JP2011520783A - インドールアミン２，３−ジオキシゲナーゼに基づく免疫療法 - Google Patents

インドールアミン２，３−ジオキシゲナーゼに基づく免疫療法 Download PDF

Info

Publication number
JP2011520783A
JP2011520783A JP2011504314A JP2011504314A JP2011520783A JP 2011520783 A JP2011520783 A JP 2011520783A JP 2011504314 A JP2011504314 A JP 2011504314A JP 2011504314 A JP2011504314 A JP 2011504314A JP 2011520783 A JP2011520783 A JP 2011520783A
Authority
JP
Japan
Prior art keywords
ido
cells
vaccine composition
peptide
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011504314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520783A5 (OSRAM
Inventor
マズ ハルド アンデルセン，
ペール ソール ストラテン，
Original Assignee
エルレフ ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エルレフ ホスピタル filed Critical エルレフ ホスピタル
Publication of JP2011520783A publication Critical patent/JP2011520783A/ja
Publication of JP2011520783A5 publication Critical patent/JP2011520783A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2011504314A 2008-04-17 2009-04-17 インドールアミン２，３−ジオキシゲナーゼに基づく免疫療法 Pending JP2011520783A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200800565 2008-04-17
DKPA200800565 2008-04-17
PCT/DK2009/000095 WO2009143843A1 (en) 2008-04-17 2009-04-17 Indoleamine 2, 3-dioxygenase based immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015052888A Division JP6016966B2 (ja) 2008-04-17 2015-03-17 インドールアミン２，３−ジオキシゲナーゼに基づく免疫療法

Publications (2)

Publication Number Publication Date
JP2011520783A true JP2011520783A (ja) 2011-07-21
JP2011520783A5 JP2011520783A5 (OSRAM) 2012-05-24

Family

ID=40873320

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011504314A Pending JP2011520783A (ja) 2008-04-17 2009-04-17 インドールアミン２，３−ジオキシゲナーゼに基づく免疫療法
JP2015052888A Active JP6016966B2 (ja) 2008-04-17 2015-03-17 インドールアミン２，３−ジオキシゲナーゼに基づく免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015052888A Active JP6016966B2 (ja) 2008-04-17 2015-03-17 インドールアミン２，３−ジオキシゲナーゼに基づく免疫療法

Country Status (20)

Country Link
US (7) US9433666B2 (OSRAM)
EP (3) EP2280721B1 (OSRAM)
JP (2) JP2011520783A (OSRAM)
CN (2) CN102088994B (OSRAM)
AU (1) AU2009253539B2 (OSRAM)
CA (1) CA2721150C (OSRAM)
CY (2) CY1120352T1 (OSRAM)
DK (2) DK3320912T3 (OSRAM)
ES (2) ES2657963T3 (OSRAM)
HR (2) HRP20180282T1 (OSRAM)
HU (2) HUE037973T2 (OSRAM)
IL (1) IL208781A (OSRAM)
LT (2) LT3320912T (OSRAM)
NO (1) NO2280721T3 (OSRAM)
NZ (1) NZ588757A (OSRAM)
PL (2) PL3320912T3 (OSRAM)
PT (2) PT2280721T (OSRAM)
SI (2) SI2280721T1 (OSRAM)
WO (1) WO2009143843A1 (OSRAM)
ZA (1) ZA201008056B (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533182A (ja) * 2014-09-17 2017-11-09 ヘアレウ ホスピタル トリプトファン２，３−ジオキシゲナーゼまたはそのフラグメントを含むワクチン組成物
JP2019537432A (ja) * 2016-10-04 2019-12-26 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 標的化エフェクタータンパク質およびその使用
US11407797B2 (en) 2017-10-11 2022-08-09 University Of Florida Research Foundation, Incorporated Modified gal-1 proteins and uses thereof

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102088994B (zh) 2008-04-17 2014-06-25 海莱乌医院 基于吲哚胺2，3-双加氧酶的免疫疗法
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
CA2947650C (en) * 2014-05-29 2021-04-27 Spring Bioscience Corporation Anti- indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof
CN106148276A (zh) * 2015-04-16 2016-11-23 中国科学院上海生命科学研究院 间充质干细胞在制备治疗神经退行性疾病的药物中的应用
JP6654207B2 (ja) 2015-06-29 2020-02-26 オーエスイー・イミュノセラピューティクス 短鎖ペプチド抗腫瘍ワクチンを用いて早期のｔメモリー応答を誘発する方法。
AU2016322506B2 (en) 2015-09-16 2023-02-09 Io Biotech Aps Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof
US20190343940A1 (en) 2016-03-04 2019-11-14 Io Biotech Aps Combination therapy against cancer
AU2017276498A1 (en) 2016-06-10 2019-01-03 Io Biotech Aps CALR and JAK2 vaccine compositions
CA3038184A1 (en) * 2016-10-14 2018-04-19 Universitat Zurich Indoleamine-2,3-dioxygenase assay for prostate cancer diagnosis and prognosis
JP7726625B2 (ja) * 2017-01-20 2025-08-20 アタラ バイオセラピューティクス，インコーポレーテッド 自家ｔ細胞を用いた多発性硬化症の処置方法
TWI796314B (zh) * 2017-01-27 2023-03-21 德商英麥提克生物技術股份有限公司 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
EA201991444A1 (ru) 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
CR20210128A (es) 2017-01-27 2021-04-26 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cancer (divisional exp. 2019-388)
BR112020010656A2 (pt) 2017-11-27 2020-11-10 Ose Immunotherapeutics tratamento aprimorado de câncer
CN109758467B (zh) * 2019-03-08 2020-12-25 中国农业科学院兰州兽医研究所 一种吉西他滨在制备预防口蹄疫病毒感染的药物中的应用
US20230210984A1 (en) * 2019-10-23 2023-07-06 The Council Of The Queensland Institute Of Medical Research Adoptive immunotherapy
EP4176053A4 (en) * 2020-07-02 2024-12-25 The Regents of the University of California PERSISTENT MEMORY T CELL RESPONSES TO CANCER AND INFECTIOUS DISEASE ANTIGENS BY MANIPULATION OF AMINO ACID CATABOLIC PATHWAYS
CN112881269A (zh) * 2021-02-23 2021-06-01 浙江正熙生物技术股份有限公司 一种流式荧光检测试剂的质量检测方法
GB202103673D0 (en) 2021-03-17 2021-04-28 Io Biotech Aps Combination therapy for cancer
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
CN114657158B (zh) * 2022-05-25 2022-10-21 深圳吉诺因生物科技有限公司 Ido1相关疫苗及其应用
US20240238384A1 (en) * 2023-01-17 2024-07-18 Regeneron Pharmaceuticals, Inc. Treatment Of B27-Negative Uveitis With Inositol Polyphosphate Multikinase (IPMK) Therapeutic Agents Or Indoleamine 2,3-dioxygenase 2 (IDO2) Agonists
EP4669344A2 (en) * 2023-02-21 2025-12-31 Salvitus, Inc. Recombinant phages, probiotic vaccines and therapeutic agents, combined compositions and methods of use
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
BR9608804A (pt) * 1995-06-20 1999-02-17 Merck & Co Inc Processos para sintetizar (1s,2r) indandiol para sintetizar (1s) amino (2r) indanol substancialmente isento de qualquer estereoisômero de bio-resolução para remover cis (1s,2r) indandiol de uma mistura de cis (1s,2r) indandiol e cis (1r,2s) indandiol e cultura pura
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
CN1221349A (zh) 1996-06-12 1999-06-30 郭亚军 细胞疫苗、免疫治疗以及它们的制备方法
CN1223688A (zh) * 1996-06-27 1999-07-21 纳幕尔杜邦公司 对羟基苯丙酮酸双加氧酶的植物基因
DE19730066A1 (de) * 1997-07-14 1999-01-21 Basf Ag DNA-Sequenz codierend für eine Hydroxyphenylpyruvatdioxygenase und deren Überproduktion in Pflanzen
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
AU4697600A (en) 1999-05-03 2000-11-17 Ludwig Institute For Cancer Research Methods for increasing t cell proliferation
JP2005503760A (ja) 2001-01-24 2005-02-10 プロテイン デザイン ラブス， インコーポレイテッド 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
US20030087250A1 (en) 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
US20060292618A1 (en) 2002-04-12 2006-12-28 Mellor Andrew L Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
EP2177601A1 (en) 2002-04-12 2010-04-21 Medical College of Georgia Research Institute, Inc Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
AU2003298786A1 (en) 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
AU2003302820A1 (en) 2002-12-05 2004-06-30 Diadexus, Inc. Compositions, splice variants and methods relating to breast specific genes and proteins
MXPA05006306A (es) 2002-12-13 2005-09-21 Mitra Medical Technology Ab Agentes de direccionamiento antilinfoma con funciones efectoras y de afinidad enlazados a traves de un reactivo trifuncional.
DE10261223A1 (de) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
EP1613308A4 (en) 2003-03-27 2008-02-20 Lankenau Inst Medical Res CANCER TREATMENT METHODS
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
US20050186289A1 (en) 2003-04-01 2005-08-25 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
WO2005017163A2 (en) 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
WO2005036127A2 (en) 2003-10-02 2005-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying target cell cytolytic lymphocytes in a sample
AU2005262164A1 (en) * 2004-07-13 2006-01-19 The University Of British Columbia Indoleamine 2,3-dioxygenase (IDO) inhibitors
WO2006056304A2 (en) 2004-11-23 2006-06-01 Institut Pasteur Control of indoleamine 2,3 deoxygenase expression and activity
EP1853305B1 (en) 2005-02-04 2014-08-20 Survac ApS Survivin peptide vaccine
WO2006122150A1 (en) 2005-05-10 2006-11-16 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
US7468186B2 (en) 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
DK1926813T4 (da) * 2005-09-23 2019-08-19 Tigenix S A U Cellepopulationer med immunregulatorisk aktivitet, fremgangsmåde til isolering og anvendelser
WO2007095050A2 (en) 2006-02-09 2007-08-23 Incyte Corporation N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
WO2007115068A2 (en) 2006-03-30 2007-10-11 Indiana University Research And Technology Corporation Genetic variants in the indoleamine 2,3-dioxygenase gene
EP2023715B1 (en) * 2006-05-18 2014-01-08 Lankenau Institute for Medical Research Indoleamine-2, 3-dioxygenase-2
US8507434B2 (en) * 2007-01-03 2013-08-13 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
CN102088994B (zh) * 2008-04-17 2014-06-25 海莱乌医院 基于吲哚胺2，3-双加氧酶的免疫疗法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6013049255; Ｃｌｉｎｉｃａｌ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．１２，Ｎｏ．４, 2006, ｐ１１４４-１１５１ *
JPN6013049258; Ｃｌｉｎｉｃａｌ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．１１，Ｎｏ．１６, 2005, ｐ６０３０-６０３９ *
JPN6013049261; Ｊｏｕｒｎａｌ　ｏｆ　Ｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ．１６４，Ｎｏ．７, 2000, ｐ３５９６-３５９９ *
JPN6013049263; 実験医学 Ｖｏｌ．２０，Ｎｏ．１３, 2002, ｐ１９４７-１９５１ *
JPN6013049266; Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．５６，Ｎｏ．１１, 1996, ｐ２４７９-２４８３ *
JPN6013049268; Ｂｉｏｃｈｅｍｉｃａｌ　ａｎｄ　Ｂｉｏｐｈｙｓｉｃａｌ　Ｒｅｓｅａｒｃｈ　Ｃｏｍｍｕｎｉｃａｔｉｏｎ Ｖｏｌ．２０４，Ｎｏ．２, 1994, ｐ７１０-７１５ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533182A (ja) * 2014-09-17 2017-11-09 ヘアレウ ホスピタル トリプトファン２，３−ジオキシゲナーゼまたはそのフラグメントを含むワクチン組成物
JP2019537432A (ja) * 2016-10-04 2019-12-26 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 標的化エフェクタータンパク質およびその使用
US11603394B2 (en) 2016-10-04 2023-03-14 University Of Florida Research Foundation, Incorporated Targeted effector proteins and uses thereof
US11407797B2 (en) 2017-10-11 2022-08-09 University Of Florida Research Foundation, Incorporated Modified gal-1 proteins and uses thereof

Also Published As

Publication number Publication date
HUE037973T2 (hu) 2018-09-28
DK2280721T3 (da) 2018-01-29
US20220249641A1 (en) 2022-08-11
US20220202922A1 (en) 2022-06-30
EP3320912A1 (en) 2018-05-16
CA2721150C (en) 2017-09-26
US20170049868A1 (en) 2017-02-23
SI3320912T1 (sl) 2021-08-31
EP2280721B1 (en) 2017-11-15
PL3320912T3 (pl) 2021-10-25
CN104056261B (zh) 2017-01-11
US11648302B2 (en) 2023-05-16
EP2280721A1 (en) 2011-02-09
HRP20180282T1 (hr) 2018-03-23
PT3320912T (pt) 2021-05-24
US20190201512A1 (en) 2019-07-04
JP6016966B2 (ja) 2016-10-26
LT2280721T (lt) 2018-02-12
PT2280721T (pt) 2018-02-16
US11324813B2 (en) 2022-05-10
CY1120352T1 (el) 2019-07-10
EP3320912B1 (en) 2021-03-31
EP3915570A1 (en) 2021-12-01
NZ588757A (en) 2012-05-25
US10258678B2 (en) 2019-04-16
US20250319159A1 (en) 2025-10-16
LT3320912T (lt) 2021-07-12
SI2280721T1 (en) 2018-02-28
IL208781A0 (en) 2010-12-30
US20110318372A1 (en) 2011-12-29
CN102088994A (zh) 2011-06-08
NO2280721T3 (OSRAM) 2018-04-14
CY1124279T1 (el) 2022-07-22
CA2721150A1 (en) 2009-12-03
CN104056261A (zh) 2014-09-24
US12233103B2 (en) 2025-02-25
AU2009253539B2 (en) 2014-03-20
HRP20210766T1 (hr) 2021-07-23
HUE055338T2 (hu) 2021-11-29
AU2009253539A1 (en) 2009-12-03
US9433666B2 (en) 2016-09-06
PL2280721T3 (pl) 2018-04-30
JP2015129182A (ja) 2015-07-16
ES2870596T3 (es) 2021-10-27
DK3320912T3 (da) 2021-05-31
US20230233657A1 (en) 2023-07-27
ES2657963T3 (es) 2018-03-07
ZA201008056B (en) 2011-07-27
WO2009143843A1 (en) 2009-12-03
IL208781A (en) 2017-09-28
CN102088994B (zh) 2014-06-25

Similar Documents

Publication Publication Date Title
US11648302B2 (en) Indoleamine 2,3-dioxygenase based immunotherapy
JP6259763B2 (ja) Ｐｄ−ｌ１に基づく免疫療法
US11878053B2 (en) Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
JP6924747B2 (ja) Ｃ−ｃモチーフケモカイン２２（ｃｃｌ２２）またはこのフラグメントを含むワクチン組成物
HK1247114A1 (en) Indoleamine 2, 3-dioxygenase based immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140327

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141119